Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
Abstract Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for patients with type 2 diabetes (T2D), in particular for older people. Newer glucose-low...
Main Authors: | Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Paola Caruso, Katherine Esposito |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12933-021-01213-w |
Similar Items
-
SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
by: Dario Giugliano, et al.
Published: (2021-12-01) -
Class effect for SGLT-2 inhibitors: a tale of 9 drugs
by: Dario Giugliano, et al.
Published: (2019-07-01) -
Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
by: Dario Giugliano, et al.
Published: (2020-03-01) -
Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized
by: Stephen J Wood, et al.
Published: (2022-07-01) -
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
by: Dario Giugliano, et al.
Published: (2021-10-01)